Icariin: A Potential Neuroprotective Agent in Alzheimer's Disease and Parkinson's Disease

Neurochem Res. 2022 Oct;47(10):2954-2962. doi: 10.1007/s11064-022-03667-0. Epub 2022 Jul 8.

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases worldwide. They are characterized by the loss of neurons and synapses in special parts of the central nervous system (CNS). There is no definitive treatment for AD and PD, but extensive studies are underway to identify the effective drugs which can slow the progression of these diseases by affecting the factors involved in their pathophysiology (i.e., aggregated proteins, neuroinflammation, and oxidative stress). Icariin, a natural compound isolated from Epimedii herba, is known because of its anti-inflammatory and anti-oxidant properties. In this regard, there are numerous studies indicating its potential as a natural compound against the progression of CNS disorders, such as neurodegenerative diseases. Therefore, this review aims to re-examine findings on the pharmacologic effects of icariin on factors involved in the pathophysiology of AD and PD.

Keywords: Alzheimer’s disease; Icariin; Neuroinflammation; Oxidative stress; Parkinson’s disease.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Flavonoids
  • Humans
  • Neurodegenerative Diseases* / drug therapy
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Parkinson Disease* / drug therapy

Substances

  • Flavonoids
  • Neuroprotective Agents
  • icariin